ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Trials and tribulations of TRT in women
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 193349" data-attributes="member: 13851"><p><strong>Trials and tribulations of testosterone therapy in women: Importance of adhering to the evidence</strong></p><p></p><p></p><p><u>Sexual health is an important part of women’s lives. When the sexual function is impaired, it can negatively affect the quality of life, self-image, and relationship satisfaction and lead to poorer health outcomes</u>.1,2 As many as 43.1% of women of all ages report a sexual problem, with 12% of women having or reporting a distressing sexual problem.2 <u>A biopsychosocial approach is ideal for evaluating, diagnosing, and treating women who have sexual dysfunction</u>.3</p><p></p><p></p><p></p><p></p><p><u>Testosterone treatment has been found to be effective in select postmenopausal women who are diagnosed with hypoactive sexual desire disorder (HSDD), which is characterized by low sexual desire causing distress</u>.4 However, no US Food and Drug Administration (FDA)-approved formulation of testosterone is available for women in the United States, due to its unknown long-term safety.</p><p></p><p>This has not stopped many physicians and other medical practitioners from prescribing custom-compounded or dose-reduced male products to women.5 Some prescribers have shared partial truths through Internet-based marketing to support “bioidentical” testosterone as a “natural” hormone, free of risk and with unfounded benefits,6 making it difficult for women to know whom to trust and where to go regarding their sexual health concerns.</p><p></p><p><u>In this issue of the Cleveland Clinic Journal of Medicine, Smith, and Batur7 provide a comprehensive review of the effects of androgens in women, as well as clinically relevant best practice recommendations for the use of androgens in women</u>. <u>They discuss the different types of endogenous androgens and how they interact with various biologic systems in women. They appropriately highlight how a state of “female androgen insufficiency” has not been established in women, such as exists for men, as low serum androgen levels do not reliably correlate with symptoms such as chronic fatigue or decreased mood in women</u>.<u> They also discuss the difficulty of accurately measuring testosterone levels, including pointing out that salivary testing is not recommended for clinical use</u>.</p><p></p><p></p><p></p><p></p><p>■ <strong>LABELS MATTER: DESIRE VS AROUSAL</strong></p><p><em>Nomenclature from the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition specifies the category of female sexual dysfunction called female sexual interest and arousal disorder (FSIAD),8 which may be useful for psychiatry or behavioral health practitioners, <u>but does not have support from clinical data nor practicality in the clinical settings in which practitioners manage sexual problems</u>.</em></p><p><em></em></p><p><em>Based on the published evidence, reputable organizations such as the Fourth International Consultation on Sexual Medicine and the International Society for the Study of Women’s Sexual Health have clearly stated that desire and arousal are distinct conditions. <u>Thus, the nomenclature and diagnostic criteria for HSDD and FSIAD must remain separate when diagnosing, treating, and coding female sexual dysfunction</u>.9,10 <u>In fact, the female sexual health outcome evaluated in the studies demonstrating the efficacy of testosterone in postmenopausal women was not FSIAD, but rather sexual satisfaction, sexual desire, or HSDD</u>.</em></p><p></p><p></p><p>■ <strong>NEW PUBLICATIONS</strong></p><p><em>Recently, the Global Consensus Position Statement on the Use of Testosterone Therapy for Women was published and endorsed by many respected US and international organizations such as the International Menopause Society, the Endocrine Society, the North American Menopause Society, and the International Society for the Study of Women’s Sexual Health.11 <u>One of its evidence-based and expert-supported recommendations is that the only indication for the use of testosterone in women is for treatment of postmenopausal women who have been diagnosed with HSDD and that the dosage should approximate a normal physiologic level of testosterone for a premenopausal woman</u>.</em></p><p><em></em></p><p><em><u>Importantly, the Global Consensus Position Statement recommends against compounded bioidentical testosterone therapy in view of lack of evidence of efficacy and safety and cautioned against testosterone pellets or injections, which typically result in supraphysiologic concentrations</u>. <u>Those levels may lead to long-term, irreversible side effects including voice changes and clitoromegaly</u>.</em></p><p></p><p></p><p>■<strong> ALIGNING PRACTICE WITH EVIDENCE</strong></p><p><em><u>It is important for physicians and other healthcare practitioners caring for women to ensure that their practice aligns with the evidence regarding testosterone treatment for women</u>. There is a great need for comprehensive sexual health treatment, given the significant numbers of women suffering from sexual problems.<u> For those select women with HSDD, transdermal testosterone, properly dosed and monitored, can provide important improvements in quality of life and sexual function</u>. </em></p><p><em></em></p><p><em><u>Testosterone should not be touted as a treatment for improving energy, well-being, or other outcomes that are not supported by data, especially with formulations that put women at risk of supraphysiologic levels</u>. Smith and Batur’s review provides a clinically relevant and valuable summary to communicate this important message. </em></p></blockquote><p></p>
[QUOTE="madman, post: 193349, member: 13851"] [B]Trials and tribulations of testosterone therapy in women: Importance of adhering to the evidence[/B] [U]Sexual health is an important part of women’s lives. When the sexual function is impaired, it can negatively affect the quality of life, self-image, and relationship satisfaction and lead to poorer health outcomes[/U].1,2 As many as 43.1% of women of all ages report a sexual problem, with 12% of women having or reporting a distressing sexual problem.2 [U]A biopsychosocial approach is ideal for evaluating, diagnosing, and treating women who have sexual dysfunction[/U].3 [U]Testosterone treatment has been found to be effective in select postmenopausal women who are diagnosed with hypoactive sexual desire disorder (HSDD), which is characterized by low sexual desire causing distress[/U].4 However, no US Food and Drug Administration (FDA)-approved formulation of testosterone is available for women in the United States, due to its unknown long-term safety. This has not stopped many physicians and other medical practitioners from prescribing custom-compounded or dose-reduced male products to women.5 Some prescribers have shared partial truths through Internet-based marketing to support “bioidentical” testosterone as a “natural” hormone, free of risk and with unfounded benefits,6 making it difficult for women to know whom to trust and where to go regarding their sexual health concerns. [U]In this issue of the Cleveland Clinic Journal of Medicine, Smith, and Batur7 provide a comprehensive review of the effects of androgens in women, as well as clinically relevant best practice recommendations for the use of androgens in women[/U]. [U]They discuss the different types of endogenous androgens and how they interact with various biologic systems in women. They appropriately highlight how a state of “female androgen insufficiency” has not been established in women, such as exists for men, as low serum androgen levels do not reliably correlate with symptoms such as chronic fatigue or decreased mood in women[/U].[U] They also discuss the difficulty of accurately measuring testosterone levels, including pointing out that salivary testing is not recommended for clinical use[/U]. ■ [B]LABELS MATTER: DESIRE VS AROUSAL[/B] [I]Nomenclature from the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition specifies the category of female sexual dysfunction called female sexual interest and arousal disorder (FSIAD),8 which may be useful for psychiatry or behavioral health practitioners, [U]but does not have support from clinical data nor practicality in the clinical settings in which practitioners manage sexual problems[/U]. Based on the published evidence, reputable organizations such as the Fourth International Consultation on Sexual Medicine and the International Society for the Study of Women’s Sexual Health have clearly stated that desire and arousal are distinct conditions. [U]Thus, the nomenclature and diagnostic criteria for HSDD and FSIAD must remain separate when diagnosing, treating, and coding female sexual dysfunction[/U].9,10 [U]In fact, the female sexual health outcome evaluated in the studies demonstrating the efficacy of testosterone in postmenopausal women was not FSIAD, but rather sexual satisfaction, sexual desire, or HSDD[/U].[/I] ■ [B]NEW PUBLICATIONS[/B] [I]Recently, the Global Consensus Position Statement on the Use of Testosterone Therapy for Women was published and endorsed by many respected US and international organizations such as the International Menopause Society, the Endocrine Society, the North American Menopause Society, and the International Society for the Study of Women’s Sexual Health.11 [U]One of its evidence-based and expert-supported recommendations is that the only indication for the use of testosterone in women is for treatment of postmenopausal women who have been diagnosed with HSDD and that the dosage should approximate a normal physiologic level of testosterone for a premenopausal woman[/U]. [U]Importantly, the Global Consensus Position Statement recommends against compounded bioidentical testosterone therapy in view of lack of evidence of efficacy and safety and cautioned against testosterone pellets or injections, which typically result in supraphysiologic concentrations[/U]. [U]Those levels may lead to long-term, irreversible side effects including voice changes and clitoromegaly[/U].[/I] ■[B] ALIGNING PRACTICE WITH EVIDENCE[/B] [I][U]It is important for physicians and other healthcare practitioners caring for women to ensure that their practice aligns with the evidence regarding testosterone treatment for women[/U]. There is a great need for comprehensive sexual health treatment, given the significant numbers of women suffering from sexual problems.[U] For those select women with HSDD, transdermal testosterone, properly dosed and monitored, can provide important improvements in quality of life and sexual function[/U]. [U]Testosterone should not be touted as a treatment for improving energy, well-being, or other outcomes that are not supported by data, especially with formulations that put women at risk of supraphysiologic levels[/U]. Smith and Batur’s review provides a clinically relevant and valuable summary to communicate this important message. [/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Trials and tribulations of TRT in women
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top